Sepsis: A Review of Advances in Management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Novosad SA, Sapiano MRP, Grigg C, et al. Vital signs: epidemiology of sepsis: prevalence of health care factors and opportunities for prevention. Morb Mortal Wkly Rep. 2016;65(33):864–9.
Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):1303–10.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801.
Kushimoto S, Gando S, Saitoh D, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care. 2013;17(6):R271.
Doerr F, Badreldin AM, Heldwein MB, et al. A comparative study of four intensive care outcome prediction models in cardiac surgery patients. J Cardiothorac Surg. 2011;6:21.
Minne L, Abu-Hanna A, deJonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12(6):R161.
Lee YI, Smith RL, Gartshteyn Y, Kwon S, Caraher EJ, Nolan A. Predictors of acute hemodynamic decompensation in early sepsis: an observational study. J Clin Med Res. 2016;8(8):575–81.
Lokhandwala S, Moskowitz A, Lawniczak R, Giberson T, Cocchi MN, Donnino MW. Disease heterogeneity and risk stratification in sepsis-related occult hypoperfusion: a retrospective cohort study. J Crit Care. 2015;30(3):531–6.
Vincent J-L. The clinical challenge of sepsis identification and monitoring. PLoS Med. 2016;13(5):e1002022.
Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
Dupuy A-M, Philippart F, Péan Y, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I—currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3(1):22.
Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect. 2005;11:101–8.
Miglietta F, Faneschi ML, Lobreglio G, Palumbo CRA. Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis. Le Infez Med. 2015;3:230–7.
Hofer N, Zacharias E, Müller W, Resch B. An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. Neonatology. 2012;102:25–36.
Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery. 2015;157:362–80.
Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol. 2011;135(2).
Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically Ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.
Ahn S, Kim WY, Kim S-H, et al. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respir Viruses. 2011;5(6):398–403.
Juskewitch JE, Abraham RS, League SC, et al. Monocyte HLA-DR expression and neutrophil CD64 expression as biomarkers of infection in critically ill neonates and infants. Pediatr Res. 2015;78(6):683–90.
Cazalis M-A, Friggeri A, Cavé L, et al. Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock. Crit Care. 2013;17(6):R287.
Vester H, Dargatz P, Huber-Wagner S, Biberthaler P, van Griensven M. HLA-DR expression on monocytes is decreased in polytraumatized patients. Eur J Med Res. 2015;20:84.
Das U. HLA-DR expression, cytokines and bioactive lipids in sepsis. Arch Med Sci. 2014;10(2):325–35.
Rhee C, Murphy MV, Li L, Platt R, Klompas M. Centers for disease control and prevention PreventionEpicenters Program. Lactate testing in suspected sepsis: trends and predictors of failure to measure levels. Crit Care Med. 2015;43(8):1669–76.
Holder AL, Gupta N, Lulaj E, et al. Predictors of early progression to severe sepsis or shock among emergency department patients with nonsevere sepsis. Int J Emerg Med. 2016;9(1):10.
Vincent J-L, Quintairos E, Silva A, Couto L, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care. 2016;20(1):257.
Bhat SR, Swenson KE, Francis MW, Wira CR. Lactate clearance predicts survival among patients in the emergency department with severe sepsis. West J Emerg Med. 2015;16(7):1118–26.
Bolvardi E, Malmir J, Reihani H, et al. The role of lactate clearance as a predictor of organ dysfunction and mortality in patients with severe sepsis. Mater Sociomed. 2016;28(1):57–60.
He H, Liu D, Long Y, et al. High central venous-to-arterial CO2 difference/arterial-central venous O2 difference ratio is associated with poor lactate clearance in septic patients after resuscitation. J Crit Care. 2016;31(1):76–81.
Naumann DN, Midwinter MJ, Hutchings S. Venous-to-arterial CO2 differences and the quest for bedside point-of-care monitoring to assess the microcirculation during shock. Ann Transl Med. 2016;4(2):37.
Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816–24.
Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:232.
Saukkonen K, Lakkisto P, Pettilä V, et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem. 2008;54(6):1000–7.
Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60.
Harrois A, Huet O, Duranteau J. Alterations of mitochondrial function in sepsis and critical illness. Curr Opin Anaesthesiol. 2009;22:143.
Valenzuela Sánchez F, Bohollo de Austria R, Monge García I, Gil A. Shock séptico. Med Intensiva. 2005;29(3):192–200.
Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311:1308.
McPherson D, Griffiths C, Williams M et al. Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010. BMJ Open 2013;3.
Blanco J, Muriel-Bombín A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12:R158.
Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296.
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96.
Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749.
Whiles BB, Deis AS, Simpson SQ. Increased time to initial antimicrobial administration is associated with progression to septic shock in severe sepsis patients. Crit Care Med. 2017;45:623–9.
Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med. 2015;43:1907–15.
Stephan Harbarth, Jorge Garbino, JéromePugin, Jacques A Romand, Daniel Lew, Didier Pittet Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115(7):529–535.
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31(12):2742–51.
Mc Growan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 1983;5:1033–48.
Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298–314.
Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045.
Donnino MW, Nguyen B, Jacobsen G, Tomianovich M, Rivers E. Cryptic septic shock: a subanalysis of early, goal-directed therapy. Chest. 2003;124:90S-b.
Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Med. 2007;33:1892–9.
Puskarich MA, Trzeciak S, Shapiro NI, Heffner AC, Kline JA, Jones AE, Emergency Medicine Shock Research Network (EMSHOCKNET). Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock. Resuscitation. 2011;82(10):1289–93.
Gu WJ, Zhang Z, Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. Intensive Care Med. 2015;41:1862–3.
Postelnicu R, Evans L. Monitoring of the physical exam in sepsis. Curr Opin Crit Care. 2017;23:232–6.
Ait-Oufella H, Lemoinne S, Boelle PY, et al. Mottling score predicts survival in septic shock. Intensive Care Med. 2011;37:801–7.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzi A, Knoblich B, et al. Early goal-directed therapy in thetreatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.
Smith T, Grounds RM, Rhodes A. Central venous pressure: uses and limitations. In: Pinsky MR, Payen D, editors. Functional hemodynamic monitoring. Berlin: Springer; 2006. p. 99–110.
Ospina-Tascon G, Neves AP, Occhipinti G, Donadello K, Büchele G, Simion D, Chierego ML, Silva TO, Fonseca A, Vincent JL, De Backer D. Effects of fluids on microvascular perfusion in patients with severe sepsis. Intensive Care Med. 2010;36(6):949–55.
Farquhar IK. Continuous direct and indirect blood pressure measurement (Finapres) in the critically ill. Anaesthesia. 1991;46:1050.
Veremakis C, Holloran TH. The technique of monitoring arterial blood pressure. J CritIlln. 1989;4:82.
Richard JC, Bayle F, Bourdin G, Leray V, Debord S, Delannoy B, Stoian AC, Wallet F, Yonis H, Guerin C. Preload dependence indices to titrate volume expansion during septic shock: a randomized controlled trial. Crit Care. 2015;8(19):5. doi: 10.1186/s13054-014-0734-3 .
Monnet X, Rienzo M, Osman D, et al. Esophageal Doppler monitoring predicts fluid responsiveness in critically ill ventilated patients. Intensive Care Med. 2005;31:1195.
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354:2213.
Herbert P, Wells G, Blajchman M, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Eng J Med. 1999;340:409–17.
Duraraj L, Schmidt G. Fluid therapy in resuscitated sepsis. Less is more. Chest. 2008;133:252–63.
Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370:676–84.
Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, Vanwijngaerden YM, Spriet I, Wouters PJ, Vander Perre S, Langouche L, Vanhorebeek I, Walker BR, Van den Berghe G. Reduced cortisol metabolism during critical illness. N Engl J Med. 2013;368:1477–88.
Casserly B, Gerlach H, Phillips GS, Lemeshow S, Marshall JC, Osborn TM, Levy MM. Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign. Intensive Care Med. 2012;38(12):1946–54.
Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al. Effect of hydrocortisone on development of shock among patients with Severe sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;. doi: 10.1001/jama.2016.14799 .
Nasraway SA. Hyperglycemia during critical illness. JPEN. 2006;30:254–8.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–67.
NICE-SUGAR Study Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials Group, Finfer S, Chittock D, Li Y, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Hebert P, Henderson W, Heyland D, Higgins A, McArthur C, Mitchell I, Myburgh J, Robinson B, Ronco J. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med. 2015;41(6):1037–47.
Vriesendorp TM, DeVries JH, van Santen S, et al. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med. 2006;34:2714–8.
Ali NA, O’Brien JM, Dungan K, et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008;36:2316–21.
Payen JF, Dupuis C, Trouve-Buisson T, et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med. 2012;40:29.
The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–8.
Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159.
Fan E, Wilcox ME, Brower RG, et al. Recruitment maneuvers for acute lung injury: a systematic review. Am J Respir Crit Care Med. 2008;178:1156.
Hodgson C, Keating JL, Holland AE et al. Recruitment manoeuvres for adults with acute lung injury receiving mechanical ventilation. Cochrane Database Syst Rev 2009;CD006667.
Heming N, Lamothe L, Ambrosi X, Annane D. Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs. 2016;21(1):27–37.
Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther. 2011;9(11):1013–33. doi: 10.1586/eri.11.122 .
Kotsaki A, Giamarellos-Bourboulis EJ. Emerging drugs for the treatment of sepsis. Expert OpinEmerg Drugs. 2012;17(3):379–91.
Rello J, Perez A. Precision medicine for the treatment of severe pneumonia in intensive care. Expert Rev Respir Med. 2016;10:297–316.
Rello J, Valenzuela-Sánchez F. Septic shock in the era of precision medicine. J Thorac Dis. 2016;. doi: 10.21037/jtd.2016.03.83 .
Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309:1154.
Rice TW, Wheeler AP, Bernard GR, et al. A randomized, doubleblind, placebocontrolled trial of TAK242 for the treatment of severe sepsis. Crit Care Med. 2010;38:1685.
Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445.
Schadler D, Brederlau J, Jorres A, Marx G, Meier Hellmann A, Putensen C, Quintel M, Spies C, Porzelius C, Engel C, Weiler N, Kuhlmann M. Extracorporeal cytokine hemoadsorption in patients with severe sepsis and acute lung injury. Am J Respir Crit Care Med, 2013;A5241.
Honore PM, Jacobs R, JoannesBoyau O, et al. Newly designed CRRT membranes for sepsis and SIRS a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59:99.
van Deuren M, Santman FW, van Dalen R, et al. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis. 1992;15:424.
Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014;4:e003536.
JoannesBoyau O, Honoré PM, Perez P, et al. Highvolumeversusstandardvolumehaemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535.
Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37:803.
Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T. Ery- thromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchialepithelial cells. Biochem Biophys Res Commun. 2000;267:124–8. doi: 10.1006/bbrc.1999.1917 .
Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin—8 production by human monocytes through AP-1 and NF-kappaB transcription factors. J Antimicrob Chemother. 2002;49:745–55. doi: 10.1093/jac/dkf008 .
Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590–615.
Hsu BG, Lee RP, Yang FL, Harn HJ. ChenHI. Post-treatment with N- acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci. 2006;79:2010–6. doi: 10.1016/j.lfs.2006.06.040 .
Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN gamma treatment. Nat Med. 1997;3:678.
Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and metaanalysis. Crit Care Med. 2007;35:2686.
Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocyte macrophage colony stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002;166:138.
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte macrophage colony stimulating factor to reverse sepsis associated immunosuppression: a double blind, randomized, placebo controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640.
Bozza FA, Gomes RN, Japiassú AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock. 2004;22:309.
Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T cell activation. Nat Med. 2000;6:414.
Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36:2973.
Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis:a systematic review and metaanalysis. J Thromb Haemost. 2015;13:508.
Boeuf B, Gauvin F, Guerguerian AM, et al. Therapy of shock with naloxone: a metaanalysis. Crit Care Med. 1998;26:1910.
Staubach KH, Schröder J, Stüber F, et al. Effect of pentoxifylline in severe sepsis: results of a randomized, double blind, placebo controlled study. Arch Surg. 1998;133:94.
Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target invascular disease: the emergingrole of statins. J Am Coll Cardiol. 2014;63:2491–502.
Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, GershmanK Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205:13–9. doi: 10.1093/infdis/jir695 .
Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683.
Morelli A, Singer M, Raieri VM, D’Egidio A, Mascia L, Orecchioni A, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. 2016;. doi: 10.1007/s00134-016-4351-2 .
Polito A, Parisini E, Ricci Z, Picardo S, Annane D. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med. 2012;38:9–19.
Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wiśniewska H, Traber LD, et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med. 2014;42:e525–33.
Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, et al. Selective alpha7-nicotinic acetylcholine receptor ago- nist GTS-21 improves survival in murine endo- toxemia and severe sepsis. Crit Care Med. 2007;35:1139–44.
Venet F, Foray AP, Villars-Méchin A, Malcus C, Poitevin-Later F, et al. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012;189:5073–81.
Ostatin A, Paltsev A, Leplina O, Shevela Y, Chernykh H. The experience of surgical infec- tions treatment with extracorporalimmu-notherapy. Medicinskaya Immunol. 2000;2:43–51.
Li C, Bo L, Liu Q, Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015;33:90–6.
Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18:R3.
Cavaillon JM, Eisen D, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care. 2014;18:216.